Neuroendocrine colon cancer is a rare and aggressive form of cancer that starts in the cells of the colon with both nerve and ...

Researchers have been working toward using the gut microbiome as a clinical target for screening for colorectal cancer. This ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.